Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans-Reference-Cited by-同舟云学术

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Published:2017-02-16 Issue:5 Volume:60 Page:1971-1993
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Thorarensen Atli^ORCID,Dowty Martin E.¹,Banker Mary Ellen,Juba Brian,Jussif Jason,Lin Tsung,Vincent Fabien,Czerwinski Robert M.,Casimiro-Garcia Agustin,Unwalla Ray,Trujillo John I.,Liang Sidney,Balbo Paul,Che Ye,Gilbert Adam M.,Brown Matthew F.,Hayward Matthew,Montgomery Justin,Leung Louis¹,Yang Xin¹,Soucy Sarah,Hegen Martin,Coe Jotham,Langille Jonathan,Vajdos Felix,Chrencik Jill,Telliez Jean-Baptiste

Affiliation:

1. Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide R&D, 1 Burtt Road, Andover, Massachusetts 01810, United States

Funder

Pfizer

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b01694

Reference40 articles.

1. JAK Kinases in Health and Disease: An Update